Akums Drugs and Pharmaceuticals (BOM:544222) EV-to-Revenue : 2.68 (As of May. 29, 2025)

View and export this data going back to 2024. Start your Free Trial

What is Akums Drugs and Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Akums Drugs and Pharmaceuticals's enterprise value is ₹83,004 Mil. Akums Drugs and Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was ₹30,990 Mil. Therefore, Akums Drugs and Pharmaceuticals's EV-to-Revenue for today is 2.68.

The historical rank and industry rank for Akums Drugs and Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

BOM:544222' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.62 Med: 2.13 Max: 5.32
Current: 2.67

During the past 5 years, the highest EV-to-Revenue of Akums Drugs and Pharmaceuticals was 5.32. The lowest was 1.62. And the median was 2.13.

BOM:544222's EV-to-Revenue is ranked worse than
53.44% of 973 companies
in the Drug Manufacturers industry
Industry Median: 2.4 vs BOM:544222: 2.67

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-05-29), Akums Drugs and Pharmaceuticals's stock price is ₹576.10. Akums Drugs and Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was ₹199.94. Therefore, Akums Drugs and Pharmaceuticals's PS Ratio for today is 2.88.

Akums Drugs and Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Akums Drugs and Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akums Drugs and Pharmaceuticals EV-to-Revenue Chart

Akums Drugs and Pharmaceuticals Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

Mar25

EV-to-Revenue

1.64

Akums Drugs and Pharmaceuticals Quarterly Data
	Mar21	Mar22	Mar23	Sep23	Dec23	Mar24	Sep24	Dec24	Mar25
EV-to-Revenue	Get a 7-Day Free Trial				-	-	4.09	3.27	1.64

Competitive Comparison of Akums Drugs and Pharmaceuticals's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Akums Drugs and Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akums Drugs and Pharmaceuticals's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Akums Drugs and Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Akums Drugs and Pharmaceuticals's EV-to-Revenue falls into.

Save Embed

;

Save Embed

;

Akums Drugs and Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Akums Drugs and Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	83004.396	/	30990.45
	=	2.68

Akums Drugs and Pharmaceuticals's current Enterprise Value is ₹83,004 Mil.
Akums Drugs and Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹30,990 Mil.

Akums Drugs and Pharmaceuticals (BOM:544222) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Akums Drugs and Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	576.10	/	199.941
	=	2.88

Akums Drugs and Pharmaceuticals's share price for today is ₹576.10.
Akums Drugs and Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹199.94.

Akums Drugs and Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Akums Drugs and Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Akums Drugs and Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Akums Drugs and Pharmaceuticals Ltd (BOM:544222) » Definitions » EV-to-Revenue

Traded in Other Exchanges

AKUMS:India

Address

Akums House, Plot No. 131 to 133, Block C, Mangolpuri Industrial Area Phase1, Adjoining CBSE Office, Delhi, IND, 110083

Website

https://www.akums.in

Akums Drugs and Pharmaceuticals Ltd a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. Its services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and Outside markets, and other testing services. It is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs). The operates in three segments: a) Contract Development and Manufacturing Operations (CDMO), b) Active Pharmaceutical Ingredient (API), and c) Branded and Generic formulations. Key revenue is generated from Contract Development and Manufacturing Operations (CDMO).

Akums Drugs and Pharmaceuticals Headlines

No Headlines